SCHEMBL927587

SCHEMBL927587

O=c1cnc2ncccc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.48
PARP1 P09874 3/20 0.44
METAP1 P53582 2/20 0.43
METAP2 P50579 1/20 0.43
DAO P14920 2/20 0.41
MAPKAPK2 P49137 1/20 0.41
RPS6KA3 P51812 1/20 0.41
CSNK2A1 P68400 1/20 0.41
PLK3 Q9H4B4 1/20 0.41
FGFR1 P11362 2/20 0.40
FLT1 P17948 2/20 0.40
PDE5A O76074 2/20 0.40
ATAD2 Q6PL18 1/20 0.40
AURKA O14965 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HPSE Q9Y251 1/20 0.39
PDE2A O00408 1/20 0.39
PDE6D O43924 1/20 0.39
PDE8A O60658 1/20 0.39
PDE9A O76083 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL28646392 0.98 NUDT1 (0.47) NUDT1PARP1METAP1METAP2DAO
SCHEMBL11129386 0.73 ALDH1A1 (0.57) NUDT1MAPKAPK2RPS6KA3CSNK2A1PLK3
SCHEMBL1624786 0.72 NUDT1 (0.48) NUDT1PARP1METAP1METAP2DAO
SCHEMBL37862 0.71 ALDH1A1 (0.59) NUDT1MAPKAPK2RPS6KA3CSNK2A1PLK3
SCHEMBL29396007 0.71 ALDH1A1 (0.59) NUDT1MAPKAPK2RPS6KA3CSNK2A1PLK3
SCHEMBL26669218 0.70 ALDH1A1 (0.47) PARP1METAP1METAP2DAOMAPKAPK2
SCHEMBL2026047 0.69 METAP2 (0.40) METAP1METAP2MAPKAPK2RPS6KA3CSNK2A1
SCHEMBL31042178 0.69 DAO (0.53) PARP1DAOPDE5AATAD2KDM4E
SCHEMBL323981 0.69 NUDT1 (0.60) NUDT1METAP1METAP2FGFR1FLT1
Hydrochloric Acid SCHEMBL20597399 0.69 ALDH1A1 (0.57) NUDT1MAPKAPK2RPS6KA3CSNK2A1PLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113512037-B Pyridopyrazinone ionic compound and preparation method and application thereof 华南农业大学 2022-12-09 CN claimed
CN-113248493-B Fluorescent agent and method for rapidly and visually detecting carbamate pesticide residues 广州汇标检测技术中心 2022-03-25 CN claimed
CN-113512037-A Pyridopyrazinone ionic compound and preparation method and application thereof 华南农业大学 2021-10-19 CN claimed
CN-113248493-A Fluorescent agent and method for rapidly and visually detecting carbamate pesticide residues 广州汇标检测技术中心 2021-08-13 CN claimed
EP-2091951-A2 PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2009-08-26 EP claimed
WO-2007130468-A2 PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2007-11-15 WO claimed
JP-2007522200-A 2007-08-09 JP claimed
EP-1718311-A1 THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS Pfizer Products Incorporated (US) 2006-11-08 EP claimed
WO-2005079807-A1 THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-09-01 WO claimed
US-20020156089-A1 Use of CRF antagonists and related compositions PFIZER INC. 2002-10-24 US claimed
US-6465465-B1 PHOSPHODIESTERASE INHIBITORS ARZNEIMITTELWERK DRESDEN GMBH (DE) 2002-10-15 US claimed
US-20020147199-A1 PROCESS FOR THE TREATMENT OF ERECTILE DYSFUNCTION AND PRODUCT THEREFOR ARZNEIMITTELWERK DRESDEN GMBH (DE) 2002-10-10 US claimed
EP-0736532-B1 Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation ASTA MEDICA AG (DE) 2002-05-15 EP claimed
EP-1097709-A2 Use of corticotropin releasing factor antagonists for treating syndrome X Pfizer Products Inc. (US) 2001-05-09 EP claimed
EP-0992240-A1 THERAPEUTIC AGENT FOR ERECTION FAILURE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-04-12 EP claimed
EP-0736532-A1 Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation ASTA Medica Aktiengesellschaft (DE) 1996-10-09 EP claimed
US-12448368-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2025-10-21 US disclosed
US-20250171440-A1 WRN INHIBITORS NIMBUS WADJET, INC. 2025-05-29 US disclosed
US-4988705-A Antiallergens and -inflammatory agents; hypotensive agents immunological suppression; hyperproliferative skin disorders such as psoriasis SCHERING CORPORATION (US) 1991-01-29 US disclosed
US-4810708-A ANTIALLERGY, IMMUNOSUPPRESSIVE SCHERING CORPORATION (US) 1989-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171440-A1 WRN INHIBITORS WRN, BLM, RECQL NUDT1 849/4885PARP1 146/4885METAP1 3706/4885
US-20020156089-A1 Use of CRF antagonists and related compositions CRH, CRHR1, CRHR2 NUDT1 4564/4885PARP1 4840/4885METAP1 1953/4885
US-12448368-B2 Indole compounds as androgen receptor modulators AR, FSHR, ADRB3 NUDT1 3904/4885PARP1 1538/4885METAP1 3926/4885
US-20020147199-A1 PROCESS FOR THE TREATMENT OF ERECTILE DYSFUNCTION AND PRODUCT THEREFOR PDE5A, PDE3A, PDE3B NUDT1 726/4885PARP1 1283/4885METAP1 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.